© 1992

Treatment of Dementias

A New Generation of Progress

  • Edwin M. Meyer
  • James W. Simpkins
  • Jyunji Yamamoto
  • Fulton T. Crews

Part of the Advances in Behavioral Biology book series (ABBI, volume 40)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Cholinergic Drugs in Alzheimer’s Treatment

  3. Growth Factors in Alzheimer’s Treatment

    1. Front Matter
      Pages 97-98
    2. Paul A. Lapchak, Dalia M. Araujo, Millicent M. Dugich-Djordjevic, Franz Hefti
      Pages 99-111
    3. Kathleen T. Shiverick, Mohan K. Raizada, John A. Olson Jr.
      Pages 123-133
    4. Louis B. Hersh, Chuang Kong Fong, Yi-Ping Li, Craig Sampson, Gabriele Mues, Dana Hilt et al.
      Pages 135-144
    5. Tatsuo Mima, Kintomo Takakura, Shoei Furukawa, Yoshihide Hashimoto, Gunshiro Kato, Yasundo Yamasaki et al.
      Pages 157-169
    6. Millicent M. Dugich-Djordjevic, Paul A. Lapchak, Franz Hefti
      Pages 171-183
  4. Phospholipids in Alzheimer’s Treatment

    1. Front Matter
      Pages 185-185
    2. Maria Grazia Nunzi, Gino Toffano
      Pages 199-205

About this book


Alzheimer's disease is one the foremost health problems facing every society fortunate enough to attain a level of medical care that ensures an average lifespan of over 70 years of age. The cause of the disease remains unknown, and no single therapeutic approach has yet been found highly efficacious. Indeed, as the complexity of its effects on brain neuronal systems becomes elucidated, the concept emerges that Alzheimer's disease may be an umbrella term for multiple Alzheimer's-type syndromes that can be differentiated based on etiology (hereditary versus sporadic), neurochemical deficits, and extent of pathology. Whether one or more disease processes is involved, it seems increasingly unlikely that any single drug will provide efficacious relief across the broad spectrum of symptoms reflected in large subject populations. Rational therapeutic approaches may yield long term amelioration of many symptoms in selected groups of patients; and individual symptoms may be ameliorated in larger populations. Multiple approaches may be combined to optimize therapeutic effects. For example, a variety of approaches remain focused on restoration of cholinergic neurodegeneration and enhancing cholinergic neurotransmission, whereas other approaches attempt to retard the of the brain that occurs during Alzheimer's disease. Chapters cover continuous degeneration topics from growth factor secretion of proteases, which could modify amyloid processing, to neuronal gene delivery using viral vectors. The breadth and thoroughness of the chapters truly embrace a broad spectrurn of models, pathological mechanisms and therapeutic approaches.


Alzheimer CNS Nervous System Syndrom alzheimer's disease brain central nervous system dementia dopamine drug drug delivery lipide oxidative stress stress syndromes

Editors and affiliations

  • Edwin M. Meyer
    • 1
  • James W. Simpkins
    • 1
  • Jyunji Yamamoto
    • 2
  • Fulton T. Crews
    • 1
  1. 1.University of FloridaGainesvilleUSA
  2. 2.Taiho Pharmaceutical CompanyTokushimaJapan

Bibliographic information

  • Book Title Treatment of Dementias
  • Book Subtitle A New Generation of Progress
  • Editors Edwin M. Meyer
    James W. Simpkins
    Jyunji Yamamoto
    Fulton T. Crews
  • Series Title Advances in Behavioral Biology
  • DOI
  • Copyright Information Plenum Press, New York 1992
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Hardcover ISBN 978-0-306-44228-5
  • Softcover ISBN 978-1-4613-6518-1
  • eBook ISBN 978-1-4615-3432-7
  • Series ISSN 0099-6246
  • Edition Number 1
  • Number of Pages , 448
  • Number of Illustrations 31 b/w illustrations, 0 illustrations in colour
  • Topics Neurology
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Consumer Packaged Goods